Your browser doesn't support javascript.
Predicted Impacts of Booster, Immunity Decline, Vaccination Strategies, and Non-Pharmaceutical Interventions on COVID-19 Outcomes in France.
Pageaud, Simon; Eyraud-Loisel, Anne; Bertoglio, Jean-Pierre; Bienvenüe, Alexis; Leboisne, Nicolas; Pothier, Catherine; Rigotti, Christophe; Ponthus, Nicolas; Gauchon, Romain; Gueyffier, François; Vanhems, Philippe; Iwaz, Jean; Loisel, Stéphane; Roy, Pascal.
  • Pageaud S; Université de Lyon, F-69000 Lyon, France.
  • Eyraud-Loisel A; Université Claude Bernard Lyon 1, F-69622 Lyon, France.
  • Bertoglio JP; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, F-69100 Villeurbanne, France.
  • Bienvenüe A; Service de Biostatistique-Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, F-69003 Lyon, France.
  • Leboisne N; Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d'Assurances (ISFA), F-69007 Lyon, France.
  • Pothier C; Fondation du Risque, Groupe Louis Bachelier, F-75002 Paris, France.
  • Rigotti C; Université de Lyon, F-69000 Lyon, France.
  • Ponthus N; Université Claude Bernard Lyon 1, F-69622 Lyon, France.
  • Gauchon R; Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d'Assurances (ISFA), F-69007 Lyon, France.
  • Gueyffier F; CNRS UMR 5509, Laboratoire de Mécanique des Fluides et d'Acoustique (LMFA), F-69130 Écully, France.
  • Vanhems P; École Centrale de Lyon, F-69130 Lyon, France.
  • Iwaz J; Université de Lyon, F-69000 Lyon, France.
  • Loisel S; Université Claude Bernard Lyon 1, F-69622 Lyon, France.
  • Roy P; Laboratoire de Sciences Actuarielle et Financière (LSAF), Institut de Science Financière et d'Assurances (ISFA), F-69007 Lyon, France.
  • On Behalf Of The CovDyn Group Covid Dynamics; Université de Lyon, F-69000 Lyon, France.
Vaccines (Basel) ; 10(12)2022 Nov 28.
Article in English | MEDLINE | ID: covidwho-2143786
ABSTRACT
The major economic and health consequences of COVID-19 called for various protective measures and mass vaccination campaigns. A previsional model was used to predict the future impacts of various measure combinations on COVID-19 mortality over a 400-day period in France. Calibrated on previous national hospitalization and mortality data, an agent-based epidemiological model was used to predict individual and combined effects of booster doses, vaccination of refractory adults, and vaccination of children, according to infection severity, immunity waning, and graded non-pharmaceutical interventions (NPIs). Assuming a 1.5 hospitalization hazard ratio and rapid immunity waning, booster doses would reduce COVID-19-related deaths by 50-70% with intensive NPIs and 93% with moderate NPIs. Vaccination of initially-refractory adults or children ≥5 years would half the number of deaths whatever the infection severity or degree of immunity waning. Assuming a 1.5 hospitalization hazard ratio, rapid immunity waning, moderate NPIs and booster doses, vaccinating children ≥12 years, ≥5 years, and ≥6 months would result in 6212, 3084, and 3018 deaths, respectively (vs. 87,552, 64,002, and 48,954 deaths without booster, respectively). In the same conditions, deaths would be 2696 if all adults and children ≥12 years were vaccinated and 2606 if all adults and children ≥6 months were vaccinated (vs. 11,404 and 3624 without booster, respectively). The model dealt successfully with single measures or complex combinations. It can help choosing them according to future epidemic features, vaccination extensions, and population immune status.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10122033

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10122033